In two previous reports, it was shown that cocarboxylase and p-aminobenzoic acid counteract the inhibitory effect of sulfathiazole on yeast and bacterial carboxylases. Whereas cocarboxylase brings about this effect without exercising any inhibitory action on carboxylase, p-aminobenzoic acid exercises the antagonistic action to sulfathiazole while maintaining a certain degree of inhibitory effect of its own on carboxylases. That is, p-aminobenzoic acid behaves as an inhibitor and thereby counteracts the effect of other inhibitors weaker or stronger than itself.
of carboxylase activity. In the presence of 0.086 and 0.86 per cent neopeptone this inhibition was reduced to 32 and 15 per cent, respectively. Comparison of the effects exercised by neopeptone and serum albumin in counteracting the inhibition of the carboxylase activity of E. coli by para-, meta-, and ortho-aminobenzenesulfonamides,2 and para-aminobenzoic acid The results presented in table 3 show that in simple buffer medium para-, meta-, and ortho-aminobenzenesulfonamides inhibited the carboxylase activity of E. coli, respectively, 68, 43, and 100 per cent. In the presence of 0.86 per cent neopeptone the inhibitions were reduced, respectively, to 19, 7, and 10 per cent. In contrast, neopeptone did not exercise any antagonism to the inhibition by p-aminobenzoic acid. This indicates that this substance exercises a greater affinity for carboxylase than for neopeptone. Comparison of the inhibitory effects of 2.4 X 10-2 m para-, meta-, and ortho-aminobenzenesulfonamides and para-aminobenzoic acid on the carboxylase activity of E. coli in the presence of serum albumin (2 per cent) 
DISCUSSION
The results presented in this report show that the inhibition of carboxylase activity of E. coli by sulfathiazole is counteracted by neopeptone. Under similar conditions the high inhibitions exercised on E. coli carboxylase by para-, meta-, and ortho-aminobenzenesulfonamides are also counteracted by neopeptone. In contrast, the inhibition by p-aminobenzoic acid is not counteracted by neopeptone. These results indicate that neopeptone manifests greater affinity for carboxylase than these sulfonamides.
A human serum globulin fraction, composed of a mixture of alpha and beta globulins, exercised strong inhibitory effect on the carboxylase activity of E. coli. This inhibition likewise was found to be reversible by neopeptone.
Human serum albumin also exercised a measurable degree of inhibition on E. coli carboxylase. In this capacity, serum albumin was found to be incapable of counteracting the inhibition exercised by para-aminobenzenesulfonamide and para-aminobenzoic acid. In contrast, the inhibitions by meta-and orthoaminobenzenesulfonamides were abolished. With the meta isomer, in the presence of serum albumin, 40 per cent increase in the activity of carboxylase was observed. These facts show that the selective action of p-aminobenzenesulfonamide on E. coli is resistant to the reversing action of serum albumin, whereas the action by the other isomers is easily counteracted.
The resistance to 2 per cent human serum albumin of the inhibitory action exercised on a respiratory enzyme by p-aminobenzenesulfonamide (sulfanilamide), and the ease with which serum albumin abolishes the inhibitory effects of meta and ortho isomers, appears to contribute to an explanation of the antibacterial chemotherapeutic activity of the former, and the absence of activity of the latter two, in clinical practice. It is to be noted that the sulfonamideantagonizing property of neopeptone is only of theoretical, whereas that of serum albumin is both of theoretical and practical, interest. In this connection a study with E. coli by Davis (1943) is of interest. His findings and ours (Sevag, Henry, and Richardson, 1943) appear to corroborate each other. Davis found that the neutralization by 3 per cent human serum albumin of the bacteriostasis exercised by sulfonamides was most marked for sulfathiazole and least marked for sulfanilamide; with sulfapyridine and sulfadiazine it was intermediate but variable. Our results with sulfanilamide, which inhibited E. coli carboxylase, in the presence of 2 per cent fractionated serum albumin, appears to compare favorably with the results obtained by Davis.
In this connection reference to an earlier study is also of interest. Axmacher and Ludwig (1936) investigated the inhibitory effects of several aromatic sulfonic acids and germanin on the activity of a carboxylase preparation from brewers' bottom yeast (a clear, macerated yeast extract). In 3 X 10-3 M and 3 X 10-4 M concentrations germanin exercised, respectively, 95 and 91 per cent inhibition on carboxylase. Blood serum (final concentration in reaction system, 30 per cent) and 0.5 per cent Witte peptone were tested with respect to their antagonistic action on the inhibition by germanin. Blood serum completely reversed the inhibition by 3 X 10-4 M germanin. Peptone reduced the 91 per cent inhibition by 3 X 10-4 M germanin to 2 per cent, but exercised no antagonistic action against the 95 per cent inhibition by 3 X 10-3 M germanin. Evidently there is a critical concentration for each substance involved in these reactions. One-half per cent gelatin showed no reversing action in this respect.
In formulating the mechanism of these antagonistic reactions, it appears to be clear that proteins and carboxylase compete for sulfonamides (or germanin), and proteins compete with the drugs for carboxylase. According to Davis, the albumin-bound drug is ineffective, that is, the drugs enter into a "combination" with serum proteins. In view also of the fact that serum proteins inhibited carboxylase, it must be concluded that serum proteins also combine with the enzyme. Under these conditions, they may or may not exercise inhibitory effect on the activity of the enzyme, but they will be capable of preventing an inhibitory union between the drug and the enzyme. These observations can be expressed by the following scheme: That proteins enter into a combination with enzymes is evident also from the following experimental facts: inhibition of pepsin and trypsin by combining with peptonelike substances (Northrop, 1922) ; irreversible combination between urease and trypsin (Tauber and Kleiner, 1931) ; formation of "edestin-pepsin" complex (Northrop, 1933) ; inhibition of milk-coagulating properties of pepsin and rennin (Tauber, 1934) ; reversible inactivation of tobacco mosaic virus by trypsin (Bawden and Pirie, 1937) ; a reversible, mutually inhibitory combination between ascarase and trypsin (Sang, 1938) ; and a reversible combination between d-ribonuclease and tobacco mosaic virus (Loring, 1942) . (For a comprehensive discussion of these combinations, see Sevag, 1945 .) Only a careful consideration of these factors can orient us in formulating the true mechanism of the action of sulfonamides.
SUMMARY
Neopeptone counteracted the strong inhibitory effects exercised on the carboxylase activity of Escherichia coli by para-, meta, and ortho-aminobenzenesulfonamides, but showed no effect on the inhibition by p-aminobenzoic acid.
Neopeptone exercised no inhibition on carboxylase.
Neopeptone counteracted also the inhibition exercised on the carboxylase activity of E. coli by human alpha and beta globulins.
Hurman serum albumin counteracted the inhibitory effects exercised on the carboxylase activity of E. coli by meta, and ortho-aminobenzenesulfonamides, but had no effect on those exercised by p-aminobenzenesulfonamide and p-aminobenzoic acid. The relation of these observations to the clinical significance of the active drugs is discussed.
A scheme is presented which shows that drugs can combine reversibly with enzyme proteins. It also shows that foreign proteins may exercise their antisulfonamide action by combining with either enzyme proteins or drugs.
